Ignyta, Inc. (RXDX)

Oncology Corporate Profile

Stock Performance

7.5300
0.0300

HQ Location

11095 Flintkote Avenue, Suite D
San Diego, CA 92121

Company Description

Ignyta, Inc. is a trailblazing biotechnology company catalyzing personalized medicine in cancer. We are pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. We achieve this goal by leveraging our proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.

Website: http://www.ignyta.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RXDX-105multiple tyrosine kinase inhibitorVarious cancer typesII
entrectinib / RXDX-101tyrosine kinase inhibitorVarious cancer typesII

View additional information on product candidates here »

Source: http://www.ignyta.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/21/2017 06:19 am

5/21/2017 06:19 am

5/21/2017 06:19 am

5/21/2017 06:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/9/2017 12:19 pm

5/9/2017 12:19 pm

5/9/2017 12:19 pm

5/9/2017 12:19 pm

5/9/2017 12:19 pm

5/4/2017 12:19 am

5/3/2017 06:19 pm

5/2/2017 12:19 pm

5/1/2017 12:19 pm

4/27/2017 12:19 pm

4/27/2017 12:19 pm